Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250366 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01250366 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 70 participants.
The verdict
NCT01250366, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects.
Interventions
- DRUG INX-08189
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250366
The ClinicalTrials.gov registry entry for NCT01250366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INX-08189 is the first listed.
NCT01250366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01250366 about?
NCT01250366 is a clinical study titled "Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects". The purpose of this study is to determine the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects.
What is the current status of trial NCT01250366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2010-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01250366?
The interventions under investigation include: INX-08189 (DRUG).
Who is sponsoring clinical trial NCT01250366?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.